论文部分内容阅读
目的观察胺碘酮治疗冠心病室性心律失常的疗效。方法将120例冠心病室性心律失常患者随机分为治疗组及对照组,对照组口服普罗帕酮,治疗组口服胺碘酮片,比较两组的疗效及不良反应。结果经过治疗,两组患者的室早数、短阵室速数、QTc间期均有显著改善,差异有统计学意义(P<0.05);治疗组的改善情况优于对照组,差异有统计学意义(P<0.05)。两组均未出现严重的不良反应。结论胺碘酮是相对安全的药物,是治疗冠心病合并快速心律失常的首选,尤其患者有器质性心脏病心力衰竭时,可以获得满意的疗效,值得临床推广应用。
Objective To observe the effect of amiodarone on ventricular arrhythmia in patients with coronary heart disease. Methods 120 cases of CHD patients with ventricular arrhythmia were randomly divided into treatment group and control group, the control group oral propafenone, the treatment group oral amiodarone tablets, the efficacy and adverse reactions of the two groups were compared. Results After treatment, the early number of ventricular tachycardia, the number of ventricular tachycardia and QTc interval in both groups were significantly improved (P <0.05), and the improvement in the treatment group was better than that in the control group Significance (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Amiodarone is a relatively safe drug, is the treatment of coronary heart disease with tachyarrhythmias preferred, especially in patients with organic heart disease heart failure, you can get a satisfactory effect, worthy of clinical application.